Kenneth D. Paull

14.4k total citations · 5 hit papers
64 papers, 11.4k citations indexed

About

Kenneth D. Paull is a scholar working on Molecular Biology, Organic Chemistry and Computational Theory and Mathematics. According to data from OpenAlex, Kenneth D. Paull has authored 64 papers receiving a total of 11.4k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 27 papers in Organic Chemistry and 12 papers in Computational Theory and Mathematics. Recurrent topics in Kenneth D. Paull's work include Cancer therapeutics and mechanisms (21 papers), Synthesis and biological activity (15 papers) and Computational Drug Discovery Methods (12 papers). Kenneth D. Paull is often cited by papers focused on Cancer therapeutics and mechanisms (21 papers), Synthesis and biological activity (15 papers) and Computational Drug Discovery Methods (12 papers). Kenneth D. Paull collaborates with scholars based in United States, Germany and Malaysia. Kenneth D. Paull's co-authors include Michael R. Boyd, Dominic A. Scudiero, Anne Monks, Robert H. Shoemaker, Philip Skehan, Larry Rubinstein, Sean Tierney, Michael J. Currens, David T. Vistica and James W. Langley and has published in prestigious journals such as Science, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Kenneth D. Paull

63 papers receiving 11.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines

1991 2.9k citations Anne Monks, Dominic A. Scudiero et al. JNCI Journal of the National Cancer Institute profile →
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.

1988 2.1k citations Dominic A. Scudiero, Robert H. Shoemaker et al. PubMed profile →
Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen

1995 1.4k citations Michael R. Boyd, Kenneth D. Paull profile →
Comparison of In Vitro Anticancer-Drug-Screening Data Generated With a Tetrazolium Assay Versus a Protein Assay Against a Diverse Panel of Human Tumor Cell Lines

1990 859 citations Larry Rubinstein, Robert H. Shoemaker et al. JNCI Journal of the National Cancer Institute profile →
Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm

1989 816 citations Kenneth D. Paull, Robert H. Shoemaker et al. JNCI Journal of the National Cancer Institute profile →

Peers

Countries citing papers authored by Kenneth D. Paull

Since Specialization

Citations

This map shows the geographic impact of Kenneth D. Paull's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth D. Paull with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth D. Paull more than expected).

Fields of papers citing papers by Kenneth D. Paull

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth D. Paull. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth D. Paull. The network helps show where Kenneth D. Paull may publish in the future.

Co-authorship network of co-authors of Kenneth D. Paull

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth D. Paull. A scholar is included among the top collaborators of Kenneth D. Paull based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth D. Paull. Kenneth D. Paull is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo 1998 ·British Journal of Cancer ·Tracey D. Bradshaw, Dashuang Shi, Robert Schultz, Kenneth D. Paull, LR Kelland, A. Wilson, (unknown), H.H. Fiebig, Samantha Wrigley, (unknown)	62
2	Protein-Linked DNA Strand Breaks Induced by NSC 314622, a Novel Noncamptothecin Topoisomerase I Poison 1998 ·Molecular Pharmacology ·Glenda Kohlhagen, Kenneth D. Paull, Mark Cushman, Pamela Nagafuji, Yves Pommier	150
3	Reduced folate carrier gene (RFC1) expression and anti-folate resistance in transfected and non-selected cell lines 1997 ·International Journal of Cancer ·Jeffrey A. Moscow, (unknown), Timothy G. Myers, C. C. Cheng, Kenneth D. Paull, Kenneth H. Cowan	35
4	A protein expression database for the molecular pharmacology of cancer 1997 ·Electrophoresis ·Timothy G. Myers, N L Anderson, Mark Waltham, Guang Li, John K. Buolamwini, Dominic A. Scudiero, Kenneth D. Paull, Edward A. Sausville, John N. Weinstein	70
5	Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines 1997 ·Nature Medicine ·José M.P. Freije, Julia Lawrence, Melinda G. Hollingshead, Abel De La Rosa, V. L. Narayanan, Michael R. Grever, Edward A. Sausville, Kenneth D. Paull, Patricia S. Steeg	30
6	Reduced folate carrier gene (RFC1) expression and anti‐folate resistance in transfected and non‐selected cell lines 1997 ·International Journal of Cancer ·Jeffrey A. Moscow, (unknown), Timothy G. Myers, (unknown), Kenneth D. Paull, Kenneth H. Cowan	2
7	Azatoxin derivatives with potent and selective action on topoisomerase II 1995 ·Biochemical Pharmacology ·François Leteurtre, Dan L. Sackett, José S. Madalengoitia, Glenda Kohlhagen, Timothy L. Macdonald, Ernest Hamel, Kenneth D. Paull, Yves Pommier	30
8	Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the COMPARE program 1995 ·Biochemical Pharmacology ·(unknown), Anne Monks, (unknown), Daniel Zaharevitz, Kenneth D. Paull, (unknown), David A. Cooney, Harry Ford	34
9	Design and Synthesis of Ellipticinium Salts and 1,2-Dihydroellipticines with High Selectivities against Human CNS Cancers in vitro 1994 ·Journal of Medicinal Chemistry ·Jurjus Jurayj, R. D. HAUGWITZ, Ravi K. Varma, Kenneth D. Paull, John F. Barrett, Mark Cushman	25
10	Use of the Kohonen Self-organizing Map to Study the Mechanisms of Action of Chemotherapeutic Agents 1994 ·JNCI Journal of the National Cancer Institute ·William W. van Osdol, Timothy G. Myers, Kenneth D. Paull, Kurt W. Kohn, John N. Weinstein	71
11	Cytotoxicity and characterization of an active metabolite of benzamide riboside, a novel inhibitor of IMP dehydrogenase 1994 ·International Journal of Cancer ·Kamran Gharehbaghi, Kenneth D. Paull, James A. Kelley, Joseph J. Barchi, Víctor E. Márquez, David A. Cooney, Anne Monks, Dominic A. Scudiero, Karsten Krohn, Hiremagalur N. Jayaram	30
12	Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent 1993 ·Biochemical Pharmacology ·Éric Solary, François Leteurtre, Kenneth D. Paull, Dominic A. Scudiero, Ernest Hamel, Yves Pommier	40
13	Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin 1993 ·Journal of Medicinal Chemistry ·Sheng Chu Kuo, (unknown), (unknown), (unknown), Tian Wu, (unknown), (unknown), Kenneth D. Paull, Chii M. Lin	185
14	Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent 1992 ·Annals of Oncology ·Hans R. Hendriks, Jacqueline Plowman, Dan Berger, Kenneth D. Paull, H.H. Fiebig, Øystein Fodstad, (unknown), R.E.C. Henrar, Herbert M. Pinedo, Gilberto Schwartsmann	25
15	Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm breakdown → 1989 ·JNCI Journal of the National Cancer Institute ·Kenneth D. Paull, Robert H. Shoemaker, Louis Hodes, Anne Monks, Dominic A. Scudiero, Larry Rubinstein, Jacqueline Plowman, Michael R. Boyd	816
16	Reproducibility and response patterns of the ic50 values and relative cell line sensitivities from the nci human tumor cell line drug screening project 1988 ·Kenneth D. Paull, Louis Hodes, Jacqueline Plowman, A Monks, (unknown), (unknown), (unknown), M.R. Boyd	3
17	Development of human tumor cell line panels for use in disease-oriented drug screening. 1988 ·PubMed ·(unknown), Anne Monks, (unknown), (unknown), Donald L. Fine, (unknown), Betty J. Abbott, Kenneth D. Paull, Joseph G. Mayo, (unknown)	74
18	Preclinical antitumor activity of batracylin (NSC 320846) 1988 ·Investigational New Drugs ·Jacqueline Plowman, Kenneth D. Paull, Ghanem Atassi, Steadman D. Harrison, Donald J. Dykes, (unknown), V. L. Narayanan, (unknown)	35
19	In vivo antitumor activity of 6-benzyl-1,3-benzodioxole derivatives against the P388, L1210, B16, and M5076 murine models 1987 ·Journal of Medicinal Chemistry ·Leonard Jurd, V. L. Narayanan, Kenneth D. Paull	45
20	Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors. 1985 ·PubMed ·Daniel L. Dexter, David P. Hesson, Robert Ardecky, Ganne Venkata Sudhakar Rao, (unknown), Betsy A. Dusak, Kenneth D. Paull, Jacqueline Plowman, (unknown), V. L. Narayanan	80

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact